source
- Genmab shares climb after head-and-neck cancer data as Iovance and Coherus stocks fallGenmab's shares moved higher after the company released data from a head‑and‑neck cancer trial, which investors interpreted as a positive signal for the drug's potential. In contrast, Iovance and…
- Big tech and startups are building personal AI agents to analyze patients’ medical recordsIn a recent column the author notes that personal artificial-intelligence agents are poised to enter the healthcare arena. Large technology firms and emerging startups are creating platforms that…